NYRADA INC (ASX:NYR) 4 Nyrada Overview Our vision To become a high growth pharmaceutical discovery and development company specialising in early-stage drug development of novel treatments. Our strategy To develop treatments for diseases where there is an unmet clinical need, or where current treatments are suboptimal, and to monetise the value of these treatments through advancing highly optimised drug candidates towards out-licensing. Lead program NYR-BI03, is a Transient Receptor Potential Cation (TRPC) ion channel blocker. It is a novel mechanism of action designed to act as a neuroprotective treatment for stroke and traumatic brain injury (TBI) sufferers.
RkJQdWJsaXNoZXIy MjE2NDg3